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Extended-Release Hydrocodone: The Devil in Disguise or Just Misunderstood?
Abstract
Opioid abuse in the United States increased significantly over the past decade, leading to opioid-related
deaths. Approval of Zohydro ER, a product that lacks an abuse-deterrent formulation, has provoked media
controversy and aggressive legislative action from multiple stakeholders. Only the American Academy of
Pain Management has released a position statement on this medication, and individual opinion varies.
Additional single-entity extended-release hydrocodone formulations are in the pipeline, and Zohydro ER's
limited clinical utility may make the controversy associated with its approval a moot point. As with other
opioids, providers will need to assess individual patient risk versus benefit when prescribing Zohydro ER.
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Title: Extended-Release Hydrocodone: The Devil in Disguise or Just Misunderstood?
Abstract:
Opioid abuse in the United States increased significantly over the past decade leading to
increased opioid related deaths. Approval of ZohydroTM ER, a product that lacks an abuse
deterrent formulation, has provoked media controversy and aggressive legislative action from
multiple stakeholders. Only the AAPM has released a position statement on this medication, and
individual opinion varies. Additional single-entity extended release hydrocodone formulations
are in the pipeline and ZohydroTM ER’s limited clinical utility make the controversy associated
with its approval a moot point. Similarly to other opioids, providers will need to assess
individual patient risk versus benefit when prescribing ZohydroTM ER.
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Public Health:
Opioid related deaths are a United States public health crisis. In 2012, the Substance Abuse and
Mental Health Services Administration (SAMHSA) reported 4.9 million Americans used pain
relievers recreationally compared with 4.5 million the previous year.1 The National Center for
Health Statistics noted that 75% of medication overdose deaths were related to opioid use in
2010.2 For every one opioid related death there are 10 inpatient admissions for abuse, 32
emergency department visits for misuse, 130 addicted patients, and 825 nonmedical opioid
users.3 The rise in opioid related deaths corresponds to a 300% increase in opioid sales between
1999-2010.4 This opioid volume is sufficient for each US adult to take one combination
hydrocodone 5mg tablet every four hours for one month and costs health insurers $72.5 billion
annually. Approximately 131 million hydrocodone containing outpatient prescriptions were
dispensed in 2011, illustrating both high usage and the potential unmet need for a long acting
hydrocodone formulation.5
ZohydroTM ER Background:
Zohydro™ ER is a single entity hydrocodone bitartrate Schedule II controlled substance
indicated for severe pain requiring around the clock management. ZohydroTM ER is available in
10mg, 15mg, 20mg, 30mg, 40mg and 50 mg strengths, and is intended to be dosed twice daily.6
Table 1 lists the conversion factors from other commonly used opioids to ZohydroTM ER. One
randomized, double-blind, placebo controlled trial (n = 510) has been published demonstrating
chronic back pain patients with a mean pain intensity (PI) score of 7 and a mean daily morphine
equivalent usage of 83.8 mg had statistically greater increases in their average daily PI score
when maintained on placebo versus those patients treated with extended-release hydrocodone (p
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= 0.008).7 Additionally, a statistically greater number of patients maintained on placebo
discontinued therapy due to lack of efficacy compared to patients treated with extended-release
hydrocodone (p=0.001). Adverse effects reported in the study were consistent with opioid
induced adverse effects. Serious adverse effects were not considered to be related to study drug,
with the exception a case of reported anxiety.
Zohydro™ ER is formulated using Spheroidal Oral Drug Absorption System (SODAS®)
technology.8 The extended-release properties are achieved by coating soluble beads with active
drug which are further coated with a semi-permeable shell then encased in a hard gelatin capsule.
The beads are slowly released as gastrointestinal fluid penetrates the semi-permeable shell. This
formulation allows for biphasic drug distribution, however; this technology is not an abuse
deterrent formulation (ADF) leading to abuse concerns.
Mainstream Media:
The absence of ADF has generated significant media coverage, provoked political intervention,
and prompted a position statement from the American Academy of Pain Management (AAPM).
The general public has been exposed to numerous stories inaccurately reflecting ZohydroTM ER’s
potency relative to other long-acting opioids and emphasizing abuse potential without providing
context for the therapeutic benefit. While there have been a limited number of ZohydroTM ER
editorials in the medical literature, the greatest volume of commentary is within the lay press.
The additional volume of stories that the general public is exposed to serve as a how to guide for
potential abusers of a product as well as promoting the ideas that everyone is doing it, lowering
the threshold for new users to abuse a substance. A 2009 study published sought to determine
the correlation between media reporting on abuse potential of prescriptions medications and the
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increase in actual reports of abuse of these medications.9 The authors tracked overdose deaths
associated with short acting opioids relative to the number of mentions the brand and generic
medications received in the media. They determined that the increase in media mentions
preceded the increase in opioid deaths by two to six months.
Political Action:
Significant political action (table 1) has occurred in response to the Food and Drug
Administration’s (FDA) ZohydroTM ER approval despite a negative recommendation from the
Anesthetic and Analgesic Drug Products Advisory Committee (AADPAC). Twenty-nine state
Attorney Generals signed a letter to the FDA commissioner requesting revocation of
ZohydroTMER approval or requiring it to be reformulated as an abuse-deterrent product.10 They
cited concern over the product’s potential to exacerbate the current opioid abuse epidemic
through aggressive marketing and sales, overprescribing, and potential opioid tampering by
patients which may ultimately lead to overdose deaths. Similar appeals were made by five state
Attorney Generals and eight congressional members in letters to the US Department of Health
and Human Services Secretary.11,12 West Virginia Senator Joe Manchin and Massachusetts
Representative Stephen Lynch both introduced bills (S. 2134 and H.R. 4241: Act to Ban
ZohydroTM ER) requesting that it’s FDA approval be withdrawn until an ADF is available.13 At
the time of this writing, both bills were referred to their respective congressional committees for
further review.
The most aggressive legislative action was taken by in Massachusetts. They sought to ban its
prescribing, stocking, and dispensing in Massachusetts until an ADF is available.14 In reaction,
ZohydroTM ER’s manufacturer Zogenix sued the governor and Department of Public Health
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Commissioner seeking to overturn the ban. This sanction was overruled in US District Court ,
stating the governor had overstepped his authority which undermines the FDA’s ability to make
drugs available to promote and protect public health. Further, states are unable to force
manufactures to make non-FDA approved formulations. In response, the Massachusetts Board
of Registration in Medicine approved regulation 243 CMR 2.07(25) requiring prescribers to
complete a risk assessment and pain treatment agreement with patients prior to ZohydroTM ER
prescribing, participate in the state’s prescription monitoring program, educate patients on
ZohydroTM ER risks versus benefits, supply a letter of necessity, and document these actions in
the patient’s medical record.15 Similar proceedings are underway by Vermont Governor to
prohibit the sale of ZohydroTM ER.16
Professional Organizations:
Most professional pain, addiction, hospice/palliative care, pharmacy, and physician organizations
have not formally commented on ZohydroTM ER’s role in pain management or abuse potential .
Only the AAPM has released a formal statement outlining their viewpoints.17 They noted that
patients with idiosyncratic responses to other opioids may respond to hydrocodone ER. Its abuse
potential is similar than other immediate release (IR) and ER opioids, benzodiazepines,
stimulants, barbiturates, alcohol, and nicotine. The Academy identified a 9:1 ratio of patients
using to abusing opioids and commented that banning ZohydroTM ER would penalize the
patients who take their opioids appropriately to safeguard a small percentage of patients with
abuse disorders. AAPM noted that the 50mg ZohydroTM ER strength is less likely to be
prescribed than the 10mg-40mg doses, is released over 12 hours when swallowed intact, and
contains a lower equianalgesic dose than many other long-acting opioids. In an effort to balance
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opioid abuse risk with the benefit of improved chronic pain management, AAPM advises
prescribers to screen all patients for misuse and reassess risk at each encounter.
Pipeline/Future Directions:
In the NDA approval letter, the FDA acknowledges the limitations associated with voluntary
post-marketing adverse event reporting are unlikely to accurately reflect the potential for
“misuse, abuse, addiction, hyperalgesia, overdose, and death associated with the long-term use of
ER/long-acting opioid analgesics…..Zohydro™ ER”.5 Due to this concern, the FDA is requiring
Zogenix to conduct at least one prospective study to quantify the above risks. This study, which
is required to be completed by January 2018, should investigate the effect of the drug
formulation in addition to other abuse risk factors.
The controversy surrounding ZohydroTM ER may be time-limited secondary to other
manufacturers competing products. Purdue Pharma L.P. has submitted a New Drug Application
(NDA) to the FDA for a once daily single entity extended-release hydrocodone product with
abuse deterrent properties.18 Materials submitted to the FDA include data supporting efficacy,
decreased enjoyment when insufflated or chewed compared to hydrocodone powder or solution,
and lack of dose dumping. Teva Pharmaceutical Industries recently announced positive trial
results for a similar abuse deterrent product. Single doses of up to 90 mg twice daily were
studied. Teva anticipates filing an NDA by the end of 2014.19 Egalet Corporation has an
extended release product in the preclinical stage, no details are available regarding a potential
release date.20
Role in Therapy:
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We anticipate this drug will have marginal clinical utility in treating chronic pain. Similar to
other brand name opioid products, ZohydroTM ER’s cost will likely be a barrier to use and it does
not offer a unique method of delivery such as administration through a feeding tube. Previously
marketed long acting opioid ADF were not widely prescribed due to high cost and limited
insurance coverage. ZohydroTM ER may have a defined niche in patients with poor response or
idiosyncratic reactions to other opioids. Providers less familiar with prescribing long-acting
opioids may be more comfortable converting patients from immediate release hydrocodone
containing products to ZohydroTM ER than other long-acting opioid products.
Conclusion:
The increased number of opioid related deaths and lack of an ADF has caused significant
concern over the FDA’s ZohydroTM ER approval, creating an ethical conundrum for health care
professionals who are trying to balance the product’s abuse risk with potential clinical benefit in
chronic pain patients. Despite its high cost and limited therapeutic niche, ZohydroTM ER has
generated significant media attention and proposed legislative action to ban its prescribing,
stocking, and dispensing until an ADF is available. However, the buildup surrounding
ZohydroTM ER may be short lived as other manufacturers have ADF extended-release
hydrocodone products in development. The product’s narrow clinical utility is overstated by
media reporting and the abuse potential cannot be quantified relative to other commercially
available extended-release opioid products. To promote ZohydroTM ER patient safety,
prescribers are encouraged to assess abuse risk at baseline and at each follow-up visit.
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Table 1: Potential conversion for transitioning to ZohydroTM ER*
Oral opioid dose (mg)

Oral conversion factor

Hydrocodone 10mg

1

Oxycodone 10mg

1

Hydromorphone 3.75mg

2.67

Morphine 15mg

0.67

*Adapted from reference 6

